

type of report	Current report
number	42/2014
company	Pharmena Spółka Akcyjna

Obtaining a patent in Japan

The Management Board of PHARMENA S.A. declares that on 7th August 2014 it received notification that Japan Patent Office decided on granting a patent to patent application no. 2011-233155, concerning the use of 1-methylnicotinamide (1-MNA) in vascular protection, related to 1-MNA's ability to increase the level of prostacyclin. The patent ensures the Company a patent protection in the abovementioned scope in Japan. Increasing of the level of prostacyclin and regulation of endothelium functioning is incredibly significant in treatment and prevention of number of diseases, among others, in atherosclerosis, ischaemic heart disease, thrombosis, and inflammation of gastric mucosa.

This is yet another patent (previous ones were granted among others in USA, Europe, Russia, Mexico, Canada, Australia, China, and Japan) which the Company receives within patent applications concerning the use of selected pyridinium salts. In the previous years, the Company made a vast number of patent applications which ensure it a worldwide protection.

The information is made public due to the fact that it may influence the asset valuation of PHARMENA S.A. in the form of patents and patent applications for the use of active substances which PHARMENA S.A. possesses rights to, as well as because of participation in potential revenue resulting from commercialisation of the aforementioned patents and patent applications.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska - Vice President of the Board